[go: up one dir, main page]

CL2011003247A1 - Compuesto {5-[4-(1,1-dioxo-1-tiomorfolin-4-ilmetil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amida de acido ciclopropanocarboxilico, con actividad inhibidora de jak1 y jak2; composicion farmaceutica; y uso en el tratamiento de enfermedades inflamatorias, autoinmunitarias, proliferativas, entre otras. - Google Patents

Compuesto {5-[4-(1,1-dioxo-1-tiomorfolin-4-ilmetil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amida de acido ciclopropanocarboxilico, con actividad inhibidora de jak1 y jak2; composicion farmaceutica; y uso en el tratamiento de enfermedades inflamatorias, autoinmunitarias, proliferativas, entre otras.

Info

Publication number
CL2011003247A1
CL2011003247A1 CL2011003247A CL2011003247A CL2011003247A1 CL 2011003247 A1 CL2011003247 A1 CL 2011003247A1 CL 2011003247 A CL2011003247 A CL 2011003247A CL 2011003247 A CL2011003247 A CL 2011003247A CL 2011003247 A1 CL2011003247 A1 CL 2011003247A1
Authority
CL
Chile
Prior art keywords
compound
pharmaceutical composition
treatment
jak1
thiomorpholin
Prior art date
Application number
CL2011003247A
Other languages
English (en)
Inventor
Jeanne Marie Menet Christel
Kurt Smits Koen
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42562363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011003247(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of CL2011003247A1 publication Critical patent/CL2011003247A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REVELA UN COMPUESTO DE FORMULA (I) CAPAZ DE INHIBIR JAK; ESTE COMPUESTO PUEDE PREPARARSE COMO UNA COMPOSICIÓN FARMACÉUTICA, Y PUEDE USARSE PARA LA PREVENCIÓN Y EL TRATAMIENTO DE UNA DIVERSIDAD DE AFECCIONES EN MAMÍFEROS, QUE INCLUYEN HUMANOS, QUE ABARCAN, A MODO DE EJEMPLO, SIN LIMITACIÓN, AFECCIONES INFLAMATORIAS, ENFERMEDADES AUTOINMUNITARIAS, ENFERMEDADES PROLIFERATIVAS, RECHAZO DE TRASPLANTES, ENFERMEDADES QUE INVOLUCRAN EL DETERIORO DEL RECAMBIO DE CARTÍLAGO, MALFORMACIONES CONGÉNITAS DEL CARTÍLAGO Y ENFERMEDADES ASOCIADOS CON LA HIPERSECRECION DEL IL6.
CL2011003247A 2009-06-26 2011-12-21 Compuesto {5-[4-(1,1-dioxo-1-tiomorfolin-4-ilmetil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amida de acido ciclopropanocarboxilico, con actividad inhibidora de jak1 y jak2; composicion farmaceutica; y uso en el tratamiento de enfermedades inflamatorias, autoinmunitarias, proliferativas, entre otras. CL2011003247A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22068809P 2009-06-26 2009-06-26

Publications (1)

Publication Number Publication Date
CL2011003247A1 true CL2011003247A1 (es) 2012-04-13

Family

ID=42562363

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011003247A CL2011003247A1 (es) 2009-06-26 2011-12-21 Compuesto {5-[4-(1,1-dioxo-1-tiomorfolin-4-ilmetil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amida de acido ciclopropanocarboxilico, con actividad inhibidora de jak1 y jak2; composicion farmaceutica; y uso en el tratamiento de enfermedades inflamatorias, autoinmunitarias, proliferativas, entre otras.

Country Status (43)

Country Link
US (9) US8088764B2 (es)
EP (2) EP2445911B1 (es)
JP (2) JP5591925B2 (es)
KR (3) KR101696669B1 (es)
CN (2) CN102482273B (es)
AR (1) AR077220A1 (es)
AU (3) AU2010264633B2 (es)
BR (1) BRPI1015569B8 (es)
CA (1) CA2765985C (es)
CL (1) CL2011003247A1 (es)
CO (1) CO6491040A2 (es)
CR (1) CR20120016A (es)
CY (3) CY1119214T1 (es)
DK (2) DK2445911T3 (es)
DO (1) DOP2011000388A (es)
EA (1) EA021637B1 (es)
EC (1) ECSP12011626A (es)
ES (2) ES2626908T3 (es)
FR (1) FR21C1011I2 (es)
GB (1) GB2483424B (es)
HR (2) HRP20170826T1 (es)
HU (3) HUE033154T2 (es)
IL (1) IL216667A (es)
LT (3) LT3178819T (es)
MA (1) MA33448B1 (es)
ME (1) ME02699B (es)
MX (1) MX344951B (es)
MY (1) MY156664A (es)
NI (1) NI201100222A (es)
NL (1) NL301096I2 (es)
NO (1) NO2021013I1 (es)
NZ (1) NZ596838A (es)
PE (1) PE20121032A1 (es)
PL (2) PL2445911T3 (es)
PT (2) PT2445911T (es)
RS (1) RS56035B1 (es)
SG (2) SG177363A1 (es)
SI (2) SI3178819T1 (es)
SM (1) SMT201700265T1 (es)
TW (1) TWI462920B (es)
UA (1) UA107935C2 (es)
WO (1) WO2010149769A1 (es)
ZA (1) ZA201109386B (es)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
TWI462920B (zh) * 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
WO2011064631A1 (en) 2009-10-02 2011-06-03 Foamix Ltd. Surfactant-free, water-free, foamable compositions and breakable foams and their uses
EP2343294A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
AR086042A1 (es) * 2011-04-28 2013-11-13 Galapagos Nv Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias y composicion farmaceutica
CN104203233A (zh) * 2011-10-26 2014-12-10 艾米丽·A·斯坦 用于影响神经功能的药剂、方法和设备
US20130310340A1 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
ES2685985T3 (es) * 2012-06-22 2018-10-15 Galapagos Nv Aminotriazolopiridina para su uso en el tratamiento de la inflamación, y composiciones farmacéuticas de la misma
GB201302036D0 (en) * 2013-02-05 2013-03-20 Queen Mary & Westfield College Diagnosis
US20160303116A1 (en) * 2013-12-11 2016-10-20 Cephalon, Inc. Treatment of multiple sclerosis with a 1,2,4-triazolo [1,5a] pyridine derivative
GB201402070D0 (en) * 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
GB201402071D0 (en) * 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
TWI679205B (zh) 2014-09-02 2019-12-11 日商日本新藥股份有限公司 吡唑并噻唑化合物及醫藥
MA41252A (fr) 2014-12-23 2017-10-31 Gilead Sciences Inc Formes solides d'un inhibiteur d'ask 1
MX386902B (es) 2015-04-13 2025-03-19 Alfasigma Spa Metodos para el tratamiento de trastornos cardiovasculares.
AU2016248728A1 (en) * 2015-04-13 2017-10-12 Galapagos Nv Methods for the treatment of inflammatory disorders
WO2016179207A1 (en) * 2015-05-05 2016-11-10 Concert Pharmaceuticals, Inc. Deuterated filgotinib
CN105061420B (zh) * 2015-06-04 2017-09-05 南京旗昌医药科技有限公司 一种jak抑制剂的晶型及其制备方法和应用
CN104987333B (zh) * 2015-07-14 2017-01-11 苏州富士莱医药股份有限公司 一种Filgotinib的合成方法
WO2017012770A1 (en) 2015-07-23 2017-01-26 Ratiopharm Gmbh Acid addition salts of filgotinib
WO2017012773A1 (en) 2015-07-23 2017-01-26 Ratiopharm Gmbh Solid forms of filgotinib free base
WO2017012771A1 (en) 2015-07-23 2017-01-26 Ratiopharm Gmbh Crystalline filgotinib sulfonic acid addition salts
CN105198880B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物a晶型及其制备方法
CN105111206B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物e晶型及其制备方法
CN105111207B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物d晶型及其制备方法
CN105218539B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物b晶型及其制备方法
CN105198877B (zh) * 2015-09-18 2017-09-22 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物g晶型及其制备方法
CN105198878B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物f晶型及其制备方法
CN105198876B (zh) * 2015-09-18 2017-09-29 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物h晶型及其制备方法
CN105198879B (zh) * 2015-09-18 2017-09-22 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物c晶型及其制备方法
WO2017106568A1 (en) * 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and a bromodomain inhibitor for treating cancer
US20170174788A1 (en) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and an mmp9 binding protein for treating inflammatory disorders
US20170173034A1 (en) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders
CN108349974B (zh) * 2016-02-02 2021-04-30 深圳市塔吉瑞生物医药有限公司 一种取代的吡啶酰胺类化合物及其应用
TWI712604B (zh) 2016-03-01 2020-12-11 日商日本新藥股份有限公司 具jak抑制作用之化合物之結晶
CN105669669A (zh) * 2016-03-04 2016-06-15 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物的a晶型、b晶型、d晶型、g晶型和m晶型及其制备方法
CA3018610A1 (en) * 2016-03-21 2017-09-28 Crystal Pharmatech Co., Ltd Crystalline forms of hydrochloride of drug for treating or preventing jak-associated disease and preparation method thereof
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
KR102492378B1 (ko) * 2016-07-26 2023-01-27 톈진 롱보진 파마시우티컬 씨오., 엘티디. 선택적 jak 저해제로서 화합물, 및 이의 염 및 치료학적 용도
KR102506321B1 (ko) 2016-07-30 2023-03-03 브리스톨-마이어스 스큅 컴퍼니 Tlr7, tlr8 또는 tlr9 억제제로서의 디메톡시페닐 치환된 인돌 화합물
CN107759587B (zh) * 2016-08-19 2021-01-26 中国医药研究开发中心有限公司 [1,2,4]三唑并[1,5-a]吡啶类化合物及其制备方法和医药用途
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
CN109923108B (zh) 2016-09-09 2022-04-29 百时美施贵宝公司 吡啶基取代的吲哚化合物
CN107880038B (zh) * 2016-09-30 2021-09-28 中国医药研究开发中心有限公司 [1,2,4]三唑并[1,5-a]吡啶类化合物及其制备方法和医药用途
CA3043396A1 (en) 2016-11-10 2018-05-17 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases
EA039352B1 (ru) * 2017-01-19 2022-01-17 Сучжоу Лонгбайотек Фармасьютикалз Ко., Лтд. Соединение в качестве селективного ингибитора jak и его соли и терапевтическое применение
GB201702603D0 (en) 2017-02-17 2017-04-05 Galápagos Nv Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders
JOP20180018A1 (ar) * 2017-03-14 2019-01-30 Gilead Sciences Inc تركيبات صيدلية تتضمن مثبط jak
ES2909401T3 (es) 2017-08-04 2022-05-06 Bristol Myers Squibb Co Compuestos de indol sustituidos útiles como inhibidores de TLR7/8/9
ES2921020T3 (es) 2017-08-04 2022-08-16 Bristol Myers Squibb Co Compuestos de indol sustituidos con [1,2,4]triazolo[4,3-a]piridinilo
ES2945435T3 (es) 2017-11-14 2023-07-03 Bristol Myers Squibb Co Compuestos de indol sustituidos
US12030878B2 (en) 2017-12-15 2024-07-09 Bristol-Myers Squibb Company Substituted indole ether compounds
AR113959A1 (es) 2017-12-18 2020-07-01 Bristol Myers Squibb Co Compuestos de 4-azaindol
MX2020005873A (es) 2017-12-19 2020-08-13 Bristol Myers Squibb Co Compuestos de 6-azaindol.
SG11202005696YA (en) 2017-12-19 2020-07-29 Bristol Myers Squibb Co Substituted indole compounds useful as tlr inhibitors
BR112020011979A2 (pt) 2017-12-19 2020-11-17 Bristol-Myers Squibb Company compostos de indol substituídos por amida úteis como inibidores de tlr
EP3728218B1 (en) 2017-12-20 2021-12-01 Bristol-Myers Squibb Company Amino indole compounds useful as tlr inhibitors
MX2020005622A (es) 2017-12-20 2020-08-20 Bristol Myers Squibb Co Compuestos de indol sustituidos con arilo y heteroarilo.
CA3085937A1 (en) 2017-12-20 2019-06-27 Bristol-Myers Squibb Company Diazaindole compounds
GB201808575D0 (en) * 2018-05-24 2018-07-11 Galapagos Nv Methods for the treatment of psoriatic arthrits
US10815227B2 (en) 2018-08-27 2020-10-27 Cadila Healthcare Limited Processes for the preparation of filgotinib
CN112955450A (zh) 2018-10-24 2021-06-11 百时美施贵宝公司 经取代的吲哚和吲唑化合物
ES2963696T3 (es) 2018-10-24 2024-04-01 Bristol Myers Squibb Co Compuestos diméricos de indol sustituidos
CN111154711B (zh) * 2018-11-07 2022-08-05 杭州瑞普晨创科技有限公司 JAK2抑制剂在胰岛β细胞诱导分化中的应用
WO2020177705A1 (zh) * 2019-03-05 2020-09-10 苏州科睿思制药有限公司 Filgotinib的马来酸盐晶型CSI及其制备方法和用途
WO2020182159A1 (zh) 2019-03-14 2020-09-17 上海华汇拓医药科技有限公司 Jak激酶抑制剂及其制备方法和在医药领域的应用
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
PH12021552354A1 (en) * 2019-03-30 2022-09-05 Unichem Lab Ltd Novel process for the preparation of filgotinib and intermediates thereof
EP3965888B1 (en) 2019-05-09 2024-08-21 Bristol-Myers Squibb Company Substituted benzimidazolone compounds
CN110204542B (zh) * 2019-05-23 2022-05-20 四川伊诺达博医药科技有限公司 一种JAK1抑制剂Filgotinib的合成方法
CN110151738A (zh) * 2019-06-03 2019-08-23 上海基科生物化学有限公司 一种Jak2抑制剂联合虎杖苷雾化剂及其制备方法和应用
IT201900020240A1 (it) 2019-11-04 2021-05-04 Advitech Advisory And Tech Sa Procedimento per la preparazione di Filgotinib e intermedi di sintesi
AU2020378630A1 (en) 2019-11-08 2022-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
CN110878097B (zh) * 2019-11-29 2021-11-02 杭州科巢生物科技有限公司 菲格替尼的制备方法
CN111072655B (zh) * 2019-12-30 2021-12-10 深圳市坤健创新药物研究院 一种三氮唑并吡啶类化合物及其制备方法和药用组合物与应用
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN115066425B (zh) * 2020-02-13 2023-06-23 珠海联邦制药股份有限公司 Jak抑制剂在制备治疗jak激酶相关疾病药物中的应用
US20240325393A1 (en) * 2020-08-17 2024-10-03 Vyne Therapeutics Inc. Tofacitinib-containing anhydrous elastomer-based gel formulations
WO2022072238A1 (en) * 2020-10-02 2022-04-07 University Of Massachusetts Targeting polycythemia vera (pv)-initiating cells by blocking leukotriene binding to their receptors
CN115368389A (zh) * 2021-05-19 2022-11-22 奥锐特药业(天津)有限公司 一种Filgotinib中间体的制备方法
CN113773322B (zh) * 2021-11-10 2022-02-11 奥锐特药业(天津)有限公司 一种Filgotinib的制备方法
CN114409675B (zh) * 2022-01-07 2023-08-04 重庆医科大学 螺环异恶唑酮色满衍生物在制备用于治疗jak1介导的疾病药物中的用途
CN116496268A (zh) * 2022-01-18 2023-07-28 盛世泰科生物医药技术(苏州)有限公司 一种含环丙酰胺化合物及其应用
WO2023194842A1 (en) 2022-04-05 2023-10-12 Unichem Laboratories Limited Substituted tricyclic compounds and their use in rheumatoid arthritis

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ208996A (en) 1983-07-28 1989-08-29 American Cyanamid Co 5-substituted(1,2,4 triazpyrimidin-2-amine derivatives and pharmaceutical compositions
ATE283840T1 (de) 1999-01-29 2004-12-15 Chugai Pharmaceutical Co Ltd Chondrogonese promotoren und indolin-2-on derivate
WO2002087620A1 (fr) 2001-04-27 2002-11-07 Chugai Seiyaku Kabushiki Kaisha Promoteurs de la chondrogenese
US6514989B1 (en) 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
EP1601672B1 (en) 2003-02-14 2006-07-26 Pfizer Products Inc. Triazolo-pyridines as anti-inflammatory compounds
US20050222171A1 (en) 2004-01-22 2005-10-06 Guido Bold Organic compounds
ES2427136T3 (es) 2004-06-21 2013-10-29 Galapagos N.V. Métodos y medios para el tratamiento de la osteoartritis
MX2007002050A (es) 2004-08-18 2007-03-29 Pharmacia & Upjohn Co Llc Compuestos de triazolopiridina.
US7524860B2 (en) 2004-10-07 2009-04-28 Pfizer Inc. Antibacterial agents
GB0515026D0 (en) 2005-07-21 2005-08-31 Novartis Ag Organic compounds
WO2008025821A1 (en) 2006-08-30 2008-03-06 Cellzome Limited Triazole derivatives as kinase inhibitors
TW200904816A (en) 2007-06-05 2009-02-01 Takeda Pharmaceutical Fused heterocycle derivatives and use thereof
EA201000130A1 (ru) 2007-07-18 2010-08-30 Новартис Аг Бициклические гетероарильные соединения и их применение в качестве ингибиторов киназы
WO2009017954A1 (en) * 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
KR20100075881A (ko) 2007-08-31 2010-07-05 메르크 세로노 에스. 에이. 트리아졸로피리딘 화합물 및 ａｓｋ 저해제로서 이의 용도
GB0719803D0 (en) * 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
MX336271B (es) 2008-06-20 2016-01-13 Genentech Inc Compuestos de triazolopiridina inhibidores de jak y los metodos.
AU2009259853A1 (en) 2008-06-20 2009-12-23 Genentech, Inc. Triazolopyridine JAK inhibitor compounds and methods
WO2010010189A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010188A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
WO2010010186A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010187A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
WO2010010184A1 (en) 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
KR20120044966A (ko) 2009-06-05 2012-05-08 세파론, 인코포레이티드 1,2,4-트리아졸로〔1,5ａ〕 피리딘 유도체의 제조 및 용도
TWI462920B (zh) * 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
US20130310340A1 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
ES2685985T3 (es) 2012-06-22 2018-10-15 Galapagos Nv Aminotriazolopiridina para su uso en el tratamiento de la inflamación, y composiciones farmacéuticas de la misma

Also Published As

Publication number Publication date
LTPA2021504I1 (lt) 2021-04-12
ES2766573T3 (es) 2020-06-12
LT3178819T (lt) 2020-01-27
JP2012530766A (ja) 2012-12-06
CY2021008I1 (el) 2021-05-05
NL301096I1 (es) 2021-03-24
ZA201109386B (en) 2012-08-29
US20240325405A1 (en) 2024-10-03
GB2483424B (en) 2012-07-18
US12042498B2 (en) 2024-07-23
US8563545B2 (en) 2013-10-22
KR20180041262A (ko) 2018-04-23
CY2021008I2 (el) 2021-06-25
CO6491040A2 (es) 2012-07-31
EP3178819A1 (en) 2017-06-14
HUE047478T2 (hu) 2020-04-28
IL216667A (en) 2015-08-31
MY156664A (en) 2016-03-15
CY1119214T1 (el) 2018-02-14
PL3178819T3 (pl) 2020-04-30
NI201100222A (es) 2012-07-27
AU2010264633B2 (en) 2015-06-04
NL301096I2 (nl) 2021-04-12
ES2626908T3 (es) 2017-07-26
US20160296530A1 (en) 2016-10-13
CY1122649T1 (el) 2021-03-12
MA33448B1 (fr) 2012-07-03
CN102482273A (zh) 2012-05-30
GB2483424A (en) 2012-03-07
US9309244B2 (en) 2016-04-12
BRPI1015569A2 (pt) 2016-08-16
GB201200457D0 (en) 2012-02-22
KR101850716B1 (ko) 2018-04-20
PT2445911T (pt) 2017-06-12
UA107935C2 (xx) 2015-03-10
PL2445911T3 (pl) 2017-08-31
US20180000831A1 (en) 2018-01-04
US20140100220A1 (en) 2014-04-10
US20100331319A1 (en) 2010-12-30
AU2010264633A1 (en) 2011-12-22
LT2445911T (lt) 2017-06-12
KR101916194B1 (ko) 2018-11-07
HRP20200033T1 (hr) 2020-03-20
HK1167403A1 (en) 2012-11-30
AU2015218544B2 (en) 2017-04-27
DK3178819T3 (en) 2020-01-27
SG10201703497YA (en) 2017-06-29
CN104262337A (zh) 2015-01-07
IL216667A0 (en) 2012-02-29
US9707237B2 (en) 2017-07-18
BRPI1015569B8 (pt) 2021-05-25
TW201103936A (en) 2011-02-01
MX2011013450A (es) 2012-05-08
EP2445911B1 (en) 2017-03-01
US20120142678A1 (en) 2012-06-07
SG177363A1 (en) 2012-02-28
TWI462920B (zh) 2014-12-01
CN102482273B (zh) 2014-09-17
PE20121032A1 (es) 2012-08-25
ECSP12011626A (es) 2012-02-29
US10328081B2 (en) 2019-06-25
EP2445911A1 (en) 2012-05-02
KR20170007534A (ko) 2017-01-18
EA201270075A1 (ru) 2012-12-28
SI2445911T1 (sl) 2017-07-31
KR20120107919A (ko) 2012-10-04
CA2765985C (en) 2017-06-06
LTC2445911I2 (lt) 2022-09-26
CR20120016A (es) 2012-02-09
JP5591925B2 (ja) 2014-09-17
BRPI1015569B1 (pt) 2020-10-27
NO2021013I1 (no) 2021-03-23
RS56035B1 (sr) 2017-09-29
SMT201700265T1 (it) 2017-07-18
EP3178819B1 (en) 2019-12-04
FR21C1011I1 (es) 2021-05-07
US20150274722A1 (en) 2015-10-01
PT3178819T (pt) 2020-01-21
MX344951B (es) 2017-01-12
HUE033154T2 (en) 2017-11-28
AU2015218544A1 (en) 2015-09-17
US20210369727A1 (en) 2021-12-02
US8999979B2 (en) 2015-04-07
HUS2100007I1 (hu) 2021-03-29
AU2017204744A1 (en) 2017-07-27
HRP20170826T1 (hr) 2017-08-25
KR101696669B1 (ko) 2017-01-16
NZ596838A (en) 2014-01-31
SI3178819T1 (sl) 2020-02-28
CA2765985A1 (en) 2010-12-29
WO2010149769A1 (en) 2010-12-29
JP2014221825A (ja) 2014-11-27
US8088764B2 (en) 2012-01-03
AR077220A1 (es) 2011-08-10
DK2445911T3 (en) 2017-06-06
ME02699B (me) 2017-10-20
DOP2011000388A (es) 2012-04-15
FR21C1011I2 (fr) 2022-03-25
US11000528B2 (en) 2021-05-11
US20200078365A1 (en) 2020-03-12
EA021637B1 (ru) 2015-07-30

Similar Documents

Publication Publication Date Title
CL2011003247A1 (es) Compuesto {5-[4-(1,1-dioxo-1-tiomorfolin-4-ilmetil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amida de acido ciclopropanocarboxilico, con actividad inhibidora de jak1 y jak2; composicion farmaceutica; y uso en el tratamiento de enfermedades inflamatorias, autoinmunitarias, proliferativas, entre otras.
AR077221A1 (es) {5-[4-(3,3-dimetil-azetidina-1-carbonil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il} amida del acido ciclopropanocarboxilico inhibidor de quinasas janus(jak), en particular jak1, composiciones farmaceuticas que lo contienen y uso de los mismos para tratar afecciones inflamatorias, autoinmunes y proli
PE20150187A1 (es) Aminotriazolopiridina para uso en tratamiento de inflamacion y composiciones farmaceuticas de la misma
CR20110092A (es) Nuevos compuestos utiles para el tratamiento de enfermedades degenerativas e inflamatorias
MX355653B (es) Compuesto novedoso util para el tratamiento de enfermedades degenerativas e inflamatorias.
UY33503A (es) Imidazo [1,2-a]pirimidinas y piridinas sustituidas
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
AR077144A1 (es) Derivado de fenilimidazol como inhibidor de la enzima pde10a, composiciones farmaceuticas y uso de los mismos en el tratamiento de trastornos neurodegenerativos y psiquiatricos
CL2011000242A1 (es) Uso de compuestos derivados de fenilaminopirimidina para tratar talasemia alfa, delta y anemia celular falciforme, talasemia mayor, talasemia menor, talasemia e-beta o talasemia beta falciforme, o para mejorar o retrasar los sintomas de las mismas y uso de un compuesto especifico para tratar la talasemia.
MX2013001970A (es) Compuestos de pirrolopirimidina y usos de los mismos.
CO6541645A2 (es) Compuestos de indol y su uso farmaceutico
CL2008003576A1 (es) Compuestos derivados de amida del acido 6,7-dihidro-5h-imidazo[1,2-alfa]imidazol-3-carboxilico; composicion farmaceutica que los comprende; y usos en el tratamiento de una afeccion inflamatoria.
UY33372A (es) ?análogos de quinolina bi?funcionales, su uso en la manufactura de medicamentos,composiciones que los comprenden y procesos de preparacion?.
MX336276B (es) Composiciones de agentes tensoactivos y uso para composiciones acuosas.
CL2013002629A1 (es) Compuestos derivados de isoxazolidina; composicion y combinacion farmaceutica que los comprende, util para la prevencion y/o el tratamiento de las enfermedades relacionadas con la reduccion en la cantidad, la actividad o el movimiento de las celulas que participan en la inflamacion, enfermedades respiratorias, asma y epoc.
MX374105B (es) Compuestos azatricíclicos como inhibidores de tirosinas quinasas (jak) y el uso de los mismos en el tratamiento de enfermedades autoinmunes, inflamatorias y alérgicas.
UY33040A (es) Nuevas formas polimorfas de {4,6diamino-2-[1-(2-fluorobencil-1h-pirazol[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo
UA109796C2 (xx) ПРОТИГРИБКОВІ 5,6-ДИГІДРО-4H-ПІРОЛО$1,2-a]$1,4]БЕНЗОДІАЗЕПІНИ І 6H-ПІРОЛО$1,2-a]$1,4]БЕНЗОДІАЗЕПІНИ, ЗАМІЩЕНІ БІЦИКЛІЧНИМИ ПОХІДНИМИ БЕНЗОЛУ
CL2011003076A1 (es) Compuestos derivados de amidas del acido 6,7-dihidro-5h-imidazo[1,2-a]imidazol-3-carboxilico; composicion farmaceutica que los comprende; y su uso como inhibidores de la interaccion de las icam con las leucointegrinas y como antagonistas de lfa-1 para tratar una inflamacion o una afeccion inflamatoria tal como infarto al miocardio, accidente cerebrovascular, psoriasis, tiroiditis autoinmunitaria, enfermedad de crohn.
UY33010A (es) Compuestos de pirazina fusionados como sus sales, útiles para el tratamiento de enfermedades degenerativas e inflamatorias
WO2015019365A8 (en) N-cyanomethylamides as inhibitors of janus kinase
ECSP10010663A (es) Compuestos de pirazina fusionados utiles para el tratamiento de enfermedades degenarativas e inflamatorias
UY30386A1 (es) Compuestos de amida del acido 3-amino-tieno(2,3b(beta)piridina-2- carboxilico sustituido, procesos para su preparacion y usos de los mismos